RhumbLine Advisers’s Avalo Therapeutics AVTX Stock Holding History

RhumbLine Advisers’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$915K	Buy	59,704 +6,414	+12%	+$118K	﹤0.01%	2330
2026 Q2	$985K	Buy	+53,290	New	+$842K	﹤0.01%	2323
2022 Q2	–	Sell	-17	Closed	-$36K	–	3104
2022 Q1	$36K	Buy	17 +1	+6%	+$2.51K	﹤0.01%	2990
2021 Q4	$80K	Hold	16	–	–	﹤0.01%	2960
2021 Q3	$103K	Hold	16	–	–	﹤0.01%	2992
2021 Q2	$151K	Buy	16 +7	+78%	+$58.6K	﹤0.01%	2944
2021 Q1	$77K	Hold	9	–	–	﹤0.01%	2957
2020 Q4	$66K	Buy	9 +2	+29%	+$13.9K	﹤0.01%	3005
2020 Q3	$49K	Sell	7 -1	-13%	-$7.52K	﹤0.01%	2950
2020 Q2	$60K	Buy	8 +2	+33%	+$14.5K	﹤0.01%	3020
2020 Q1	$43K	Hold	6	–	–	﹤0.01%	2872
2019 Q4	$94K	Hold	6	–	–	﹤0.01%	2877
2019 Q3	$57K	Hold	6	–	–	﹤0.01%	2919
2019 Q2	$94K	Buy	+6	New	+$90.9K	﹤0.01%	2934

Other funds holding AVTX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.04B AUM 32.17% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $2.18B AUM 12.5% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

RhumbLine Advisers's AVTX Position: Q3 2026 in Review

RhumbLine Advisers increased its Avalo Therapeutics (AVTX) stake by 12% in Q3 2026, buying an estimated $118K and bringing the position to 59,704 shares worth $915K. The position accounts for ﹤0.01% of the portfolio, ranked #2330.

RhumbLine Advisers first reported a position in AVTX in Q2 2019 and has held it in 14 quarters since. The position peaked at $985K in Q2 2026. 48 funds tracked by Wall St. Rank hold AVTX as of Q3 2026.

RhumbLine Advisers held 59,704 shares of Avalo Therapeutics worth $915K as of Q3 2026.
RhumbLine Advisers bought 6,414 Avalo Therapeutics shares in Q3 2026, an estimated $118K.
Avalo Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #2330 holding.
RhumbLine Advisers first reported a position in Avalo Therapeutics in Q2 2019 and has held it in 14 quarters since.
RhumbLine Advisers's Avalo Therapeutics position peaked at $985K in Q2 2026.
48 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.